| Field | Specification |
|---|---|
| Target | |
| Alternative names | EH domain-containing protein 1; PAST homolog 1; hPAST1; Testilin; EHD1; PAST; CDABP0131 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human EHD1 recombinant protein (Position: K324-E516). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects EH domain-containing protein 1 (gene EHD1) in human, mouse and rat samples and is validated for Western blot, IHC, ICC/IF, flow cytometry and ELISA. The predicted molecular weight is 60.6 kDa, and the supplier reports an observed band at about 61 kDa.
EHD1 is an ATP-binding EH-domain protein that shapes and tubulates endosomal membranes. It regulates recycling of receptors from endosomes back to the plasma membrane and is studied in endocytic trafficking.
| Target | EH domain-containing protein 1 (gene EHD1; UniProt Q9H4M9, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3 |
| Calculated MW | 60.6 kDa |
| Observed MW | 61 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL |
| IHC (frozen sections) | 0.5–1 µg/mL |
| Immunocytochemistry / Immunofluorescence | 2 µg/mL |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human placenta tissue, human U87 cells, human Caco-2 cells, rat testis tissue, rat kidney tissue, rat ovary tissue, mouse testis tissue, mouse kidney tissue, mouse ovary tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 1:100, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human testis cancer tissue, human tonsil tissue, human placenta tissue, mouse testis tissue, rat testis tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Samples with confirmed staining (ICC/IF): A431 cells.
Samples with a confirmed signal (flow cytometry): U2OS cells, U87 cells.
Immunogen
Recombinant human EHD1 fragment (Lys324–Glu516), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places EH domain-containing protein 1 in the recycling endosome membrane, early endosome membrane and cell membrane. Tissue expression noted by UniProt (human): Highly expressed in testis. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
